The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...
Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy combination in prostate cancer. The collaboration focuses on evaluating J&J’s ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
It’s among the most common cancers affecting older men. But a diagnosis today isn’t always what it seems. By David Dodge An estimated one in eight men will be diagnosed with prostate cancer in their ...
Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...
Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...
Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...
The state of prostate cancer in the U.S. is not exactly great. Just take a look at the “Prostate cancer statistics, 2025” report from the American Cancer Society, published at the beginning of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results